Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 25, 2017
What is the competitive landscape for EMD SERONO, and when can generic versions of EMD SERONO drugs launch?
EMD SERONO has thirteen approved drugs.| Patents: | 5 |
| Tradenames: | 13 |
| Ingredients: | 8 |
| NDAs: | 13 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Emd Serono | GONAL-F | follitropin alfa/beta | INJECTABLE;SUBCUTANEOUS | 020378-003 | May 25, 2000 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Emd Serono | SEROSTIM | somatropin recombinant | INJECTABLE;INJECTION | 020604-002 | Aug 23, 1996 | BX | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Emd Serono | ZORBTIVE | somatropin recombinant | INJECTABLE;INJECTION | 021597-003 | Dec 1, 2003 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Emd Serono | NOVANTRONE | mitoxantrone hydrochloride | INJECTABLE;INJECTION | 019297-003 | Dec 23, 1987 | DISCN | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Emd Serono | GONAL-F | follitropin alfa/beta | INJECTABLE;SUBCUTANEOUS | 021765-001 | Mar 25, 2004 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Emd Serono | GONAL-F RFF REDI-JECT | follitropin alfa/beta | INJECTABLE;SUBCUTANEOUS | 021684-001 | May 25, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Emd Serono | GONAL-F RFF REDI-JECT | follitropin alfa/beta | INJECTABLE;SUBCUTANEOUS | 021684-001 | May 25, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Emd Serono | LUVERIS | lutropin alfa | INJECTABLE;SUBCUTANEOUS | 021322-001 | Oct 8, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Emd Serono | GONAL-F | follitropin alfa/beta | INJECTABLE;SUBCUTANEOUS | 021765-001 | Mar 25, 2004 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 308990 | ► Subscribe | |||||||||||||||||||||||||||
| Colombia | 5090905 | ► Subscribe | |||||||||||||||||||||||||||
| Czech Republic | 301912 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 20005145 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1610822 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9C0031 | Belgium | ► Subscribe | PRODUCT NAME: ACETATE DE CETRORELIX; REGISTRATION NO/DATE: EU/1/99/100/001 19990413 | ||||||||||||||||||||||||||
| C/GB10/022 | United Kingdom | ► Subscribe | PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTERED: UK EU/1/09/609/001 20100125; UK EU/1/09/609/002 20100125 | ||||||||||||||||||||||||||
| 01C/020 | Belgium | ► Subscribe | PRODUCT NAME: LUTROPINE ALFA; REGISTRATION NO/DATE: EU/1/00/155/001 20001129 | ||||||||||||||||||||||||||
| 90029 | Netherlands | ► Subscribe | PRODUCT NAME: CETRORELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZUUR ADDITIEZOUT, IN HET BIJZONDER CETRORELIX ACETAAT; REGISTRATION NO/DATE: EU/1/99/100/001-003 19990413 | ||||||||||||||||||||||||||
| C0024 | France | ► Subscribe | PRODUCT NAME: CORIFOLLITROPINE ALPHA; REGISTRATION NO/DATE: EU/1/09/609/001 20100125 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,120 others who get our Drug Patent Expiration Alerts:
